Conexeu Sciences (CNXU) and the GLP-1 Aesthetics Opportunity

Opening Summary

About 1 in 8 U.S. adults was taking a GLP-1 drug in late 2025, double the share from just 18 months earlier.¹ As the weight comes off, many of them are walking into an aesthetics clinic for the first time: by providers’ accounts, 63% of GLP-1 patients seeking facial treatment were not aesthetics users before.² Most injectables in the industry’s toolkit were designed for smaller-volume jobs.

As they reach their goals, many are seeking help with facial and body volume that today’s fillers were not designed to address. That’s not a bigger slice of an old market. It’s the raw material for a new one.

History says new categories are where the biggest money in aesthetics gets made. Botox®’s inventor, Dr. Alan Scott, has said he received about $4.5 million when he sold the rights in 1991^3,4; the franchise brought AbbVie about $6.37 billion in 2025.⁵ The question for investors is who builds the next category.

Conexeu Sciences (NASDAQ: CNXU) is one company working on that question. It has completed a 12-month preclinical study of its CXU™ device candidate aimed at large-volume aesthetic needs⁶[*12], and on Oct. 6, 2026, it said its lead wound-care device candidate, Ten-Minute Tissue™, built on the same platform, remains on track for a first-quarter 2027 FDA submission, subject to FDA review.⁷ CXU™ is investigational and has not been cleared or approved by the FDA for any use. Here’s the investment case, why the last three months matter, and what’s still unproven.

Key Figures

Full source citations are numbered inline and listed in the Sources section below.

Conexeu Sciences · Nasdaq: CNXUDownload CNXU Corporate PresentationDownload the Presentation →

The GLP-1 Demand Shock

This isn’t a niche trend. It’s one of the fastest shifts in consumer health in a generation, and it’s speeding up.

In KFF’s November 2025 poll, 12% of U.S. adults said they were currently taking a GLP-1 drug for weight loss, diabetes or another condition, double the 6% from 18 months earlier. Use peaked at 22% among adults aged 50 to 64.¹ Then the price of entry collapsed. Novo Nordisk launched a Wegovy® pill in January 2026 at $149 a month for starting doses paid in cash¹¹, and the FDA approved Eli Lilly’s Foundayo™ pill on April 1, 2026.¹² J.P. Morgan expects about 25 million Americans on GLP-1 treatment by 2030.¹³

The weight loss is substantial. In the main clinical trials, people taking semaglutide (Wegovy®) lost about 15% of their body weight on average over about 16 months, and people on the highest dose of tirzepatide lost about 21% over about 17 months.^14,15 For many, that success brings new aesthetic goals. A systematic review in Aesthetic Surgery Journal Open Forum describes facial volume changes after significant weight loss on GLP-1 drugs.¹⁶

Here’s the part investors should underline. McKinsey surveyed 174 U.S. aesthetics providers and found that 63% of GLP-1 patients seeking facial treatment were not active aesthetics users, about half of those had never even considered aesthetics, and skin laxity was the primary concern for many.² This isn’t existing demand shuffling between clinics. It’s a largely new customer the industry wasn’t built to serve.

The category leaders have noticed. Galderma, the maker of Restylane® and Sculptra®, has already run a Phase IV clinical program on facial volume loss after medication-driven weight loss.¹⁷ When a company that size funds a dedicated study, it suggests the demand is being taken seriously. The open question is who builds the best answer.

What Just Happened, and Why It Matters

In the past three months, Conexeu has put four building blocks in place. Each one maps to a specific piece of the investment case.

July 7, 2026: the preclinical evidence package. Conexeu completed its 12-month P.R.O.O.F. (Performance and Regeneration Outcomes of Flowable Collagen) study and reported that it met its objectives in a small-volume model (about the volume used in facial treatments), a large-volume 200cc-equivalent model, and injectable-performance benchmarks.⁶[*12]

Why it matters: A thesis built on “a new answer for GLP-1 patients” needs preclinical evidence at relevant volumes. P.R.O.O.F. is the company’s first reported animal study in which the CXU™ device candidate met its predefined objectives at both small volumes, similar to facial treatments, and a 200cc-equivalent volume[*12]. Without it, the aesthetics story would be a slide. With it, it’s a testable claim waiting for peer review.

July 14: the target market. Conexeu pointed CXU™ at large-volume body restoration, which it described as a large underserved opportunity in injectable aesthetics.¹⁸

Why it matters: Small companies rarely win head-on fights with AbbVie and Galderma over facial lines. By aiming at volumes few current fillers were designed to deliver, Conexeu is choosing a corner of the market with fewer established products. That’s the classic path of a category creator, not a me-too entrant.

August 18: the category argument. Conexeu argued that a new category, regenerative tissue restoration, is forming inside medical aesthetics, citing a 2026 review in JAAD Reviews and a regenerative aesthetics market estimated at $15.6 billion in 2025.¹⁹ These estimates define the category broadly and include biostimulators; they are not estimates of Conexeu’s addressable market.

Why it matters: The biggest outcomes in aesthetics have gone to whoever defined a new category. If dermatology researchers and market analysts are already tracking regeneration as its own segment, Conexeu isn’t asking investors to imagine a market. It’s asking them to judge whether it can help define one that’s already forming.

October 6: the manufacturing proof and the near-term catalyst. Conexeu said multiple scaled-up batches of CXU™ material met its predefined specifications, and that its wound-care 510(k) submission for Ten-Minute Tissue™ (the FDA route for a device similar to one already cleared) remains on track for the first quarter of 2027, subject to FDA review.⁷

Why it matters: This is the nearer-term foundation step. A 510(k) clearance would cover wound care only, but what the company learns from making the material at scale and taking it through an FDA review, together with the P.R.O.O.F. preclinical data, is designed to inform the aesthetics program. Conexeu builds everything on one platform⁷, so manufacturing progress in wound care builds experience across the platform, though the company’s staged pathway lists a separate formulation for aesthetics²⁰. A wound-care clearance would give the company its first commercial product, real manufacturing experience and a stronger hand in raising the money the longer aesthetics path will require. Reaffirming the timeline after it slipped once before is exactly the kind of execution signal investors should want to see.

A Toolkit That Wasn’t Built for This

Most major injectables on the market were designed to solve a different problem than large-volume restoration after significant weight loss.

In tissue-engineering research, a “scaffold” is a framework that supports the body in rebuilding the right kind of tissue for that site, rather than scar tissue.²³

Think of a hyaluronic acid filler as air in a tire. It plumps things up, but the body gradually absorbs it, and it has to be topped up every 6 to 12 months.²¹

The scale problem is even starker. A typical facial filler syringe holds about 0.8 to 1.0 mL, roughly one-fifth of a teaspoon.¹⁸ The P.R.O.O.F. large-volume model was about 200 cc-equivalent, roughly 200 times a filler syringe.[*12] And by Conexeu’s count of FDA approvals, nearly every new filler since 2006 has been a new hyaluronic acid formulation or line extension rather than a new mechanism.^20,25

“Few existing injectables were designed to restore larger volumes and remain in place. That is a requirement problem, not a marketing problem, and it is why the category remains open.”

Dr. Claudia Chavez-Munoz, Chief Scientific Officer and co-founder, Conexeu Sciences¹⁸

The Evidence So Far

Conexeu’s 12-month P.R.O.O.F. study assessed how tissue responded to CXU™ device candidate at multiple timepoints after placement under and within the skin in an animal model. It ran two arms: a small-volume arm, at about the volume used in facial treatments, followed for the full 12 months, and a larger-volume body arm.⁶[*12] The company reports it met its predefined objectives on all three pillars:

1. Small-volume arm. Objectives met in a small-volume model, similar in volume to facial treatments.⁶[*12]
2. Large-volume arm. Objectives met in a 200cc-equivalent model, a volume the company describes as roughly the scale of large-volume body restoration.⁶[*12]
3. Injectable performance. Pre-defined performance benchmarks for injectability and volumizing performance met.⁶[*12]

Full results are being prepared for peer-reviewed publication. To preserve the integrity of that process, the Company is not disclosing detailed findings, quantitative analyses, or individual histologic endpoints at this time. These are preclinical findings; they have not been peer-reviewed, and clinical significance has not been established. Preclinical volumes also don’t establish safe or appropriate dosing in people.

P.R.O.O.F. doesn’t stand alone. The underlying material has more than a decade of university research behind it, including peer-reviewed animal studies in Tissue Engineering Part A (2015)[*3], Advances in Wound Care (2021)[*7], Experimental Dermatology (2022)[*9] and Gels (2022)[*10]. In that research, the material has been characterized for cell infiltration and integration[*9][*10], blood-vessel ingrowth[*3][*6] and inflammatory profile.[*10] All of it is preclinical.

The Market

The markets around this idea are measured in billions. Conexeu is measured in millions. In my opinion, that gap is the heart of the story.

These are third-party estimates for whole categories, not Conexeu’s revenue or market share. The company has no commercial revenue today.

Why category creators win

The biggest fortunes in aesthetics have gone to whoever opened a new category, not whoever made a slightly better version of an old one. Botox’s inventor, Dr. Alan Scott, has said he sold the rights to Allergan for about $4.5 million in 1991.^3,4 In 2025, AbbVie reported $2.60 billion in global Botox Cosmetic sales and $3.77 billion in Botox Therapeutic sales, about $6.37 billion for the franchise.⁵

The Botox story is category history, and it is not a claim that Conexeu is the next Botox.

10 Reasons Why Conexeu Sciences (CNXU) Is Showing Up in Serious Conversations

1. The Demand Is New to Aesthetics

About 1 in 8 U.S. adults was taking a GLP-1 drug in late 2025, double the share 18 months earlier.¹ Of the GLP-1 patients now seeking facial treatment, 63% were not active aesthetics users and about half of those had never considered aesthetics at all, by providers’ accounts.² This is a new customer, not an old one moving between clinics.

2. The Price of Entry Collapsed This Year

Novo Nordisk launched a Wegovy® pill in January 2026 at $149 a month for starting doses paid in cash,¹¹ and the FDA approved Eli Lilly’s Foundayo™ pill on April 1, 2026.¹² J.P. Morgan expects about 25 million Americans on GLP-1 treatment by 2030.¹³ The patient population the thesis rests on is still growing.

3. The Category Leaders Have Already Moved

Galderma, the maker of Restylane® and Sculptra®, has run a Phase IV clinical program on facial volume loss after medication-driven weight loss.¹⁷ BCG puts provider revenue from GLP-1-related aesthetic care at about $0.7 billion, heading to $2.0 billion within five years.⁸ McKinsey surveyed 174 providers to measure it.² When the category leader funds a dedicated study, it suggests the demand is being taken seriously.

4. Most of the Toolkit Was Designed for Smaller Volumes

A facial filler syringe holds about 0.8 to 1.0 mL, roughly a fifth of a teaspoon; the P.R.O.O.F. large-volume model was about 200 cc-equivalent[*12].¹⁸ By Conexeu’s count of FDA approvals, nearly every new filler since 2006 has been a hyaluronic acid formulation or line extension rather than a new mechanism.^20,25 Large-volume restoration with a needle has few established options.

5. The Design Goal Is a Scaffold for Tissue Restoration

A hyaluronic acid filler is air in a tire: it plumps, is gradually absorbed and is topped up.²¹ Moved fat is surgery, and 30% to 70% of it is reabsorbed.²⁴ The CXU™ device candidate is designed to set at body temperature[*7][*9] and to provide a structural framework that supports cell infiltration and integration.[*9][*10] The company’s co-founder calls the gap a requirement problem, not a marketing problem.¹⁸

6. An Early Preclinical Read on Large Volumes

The 12-month P.R.O.O.F. study reported meeting its objectives in a small-volume model (about the volume used in facial treatments), a 200cc-equivalent body model and on injectability benchmarks.⁶[*12] It was run in animals, the result is company-reported, and the detailed findings are being prepared for peer review.

7. The Material Has a Decade of Peer-Reviewed Work Behind It

Peer-reviewed animal studies in Tissue Engineering Part A (2015)[*3], Advances in Wound Care (2021)[*7], Experimental Dermatology (2022)[*9] and Gels (2022)[*10] have characterized the material for cell infiltration and integration[*9][*10], blood-vessel ingrowth[*3][*6] and inflammatory profile.[*10] All of it is preclinical, and none of it is in people.

8. One Platform, Two Programs

The wound-care device candidate, Ten-Minute Tissue™, is headed for a 510(k) submission in the first quarter of 2027, subject to FDA review, on the same platform;⁷ aesthetics follows on a separate human-collagen formulation and a longer regulatory road.²⁰ A clearance in wound care would give the company its first product, manufacturing experience and a stronger hand in funding the aesthetics program.

9. The Operators Have Run This Market Before

CEO Miles Harrison previously ran Galderma North America, the home of Restylane.²⁷ Chief Medical Officer Dr. Brian Pilcher has built a career in wound healing, dermal fillers and injectable aesthetics.²⁸ The people pointing the platform at aesthetics have worked in it.

10. The Price Reflects the Wound Program

In my opinion, at roughly $94 million in market value,^9,10 Conexeu is priced against categories measured in billions.^8,26 The wound-care program accounts for most of that price. The aesthetics program comes along with it, as a long shot at a category that is forming whether or not Conexeu arrives.

What’s Still Unproven, and Why It Still Matters

No preclinical device company comes without risk, and Conexeu is no exception. So far CXU™ device candidate has been tested only in animals, not in people. The detailed P.R.O.O.F. findings are still being prepared for peer review, so the evidence the aesthetics case rests on is the company’s own summary.⁶ Aesthetics is the long road: the company’s own staged pathway puts it on a separate human-collagen formulation and the longer premarket approval route, with estimated market entry after 2030.²⁰ The timeline has slipped once already, from a 510(k) submission expected by June 30, 2026 to a target of March 31, 2027.⁹ Cash-pay demand can soften; U.S. Botox Cosmetic sales fell about 11% in 2025.²⁹ And a premarket approval program will need far more capital than the company has, so expect dilution or a partner that shares the upside.⁹

Those are real, and they deserve a careful read. But the risk sits beside a demand the company did not create.

One in eight U.S. adults is on the drugs,¹ most of the GLP-1 patients arriving at aesthetics clinics are new to aesthetics,² BCG puts the provider revenue at $0.7 billion heading to $2.0 billion,⁸ and Galderma has already run a dedicated study.¹⁷ Most injectables on the market were designed for smaller volumes: a filler syringe holds about a fifth of a teaspoon, and large-volume restoration runs about 200 cc.¹⁸ The company’s nearer path is the wound-care 510(k) targeted for the first quarter of 2027, subject to FDA review, built on the same platform, which, in my opinion, is how the aesthetics program gets paid for.⁷

For an investor, none of that implies a result. It implies relevance. In my opinion, at about $94 million, you are paying for a wound-care program with a long shot at a category that is forming with or without Conexeu.^9,10 The one thing to watch is the peer-reviewed publication of the P.R.O.O.F. data.⁶

The Bottom Line

The companies that make GLP-1 drugs have been priced for three years. In my opinion, the next chapter belongs to whoever serves the new aesthetic demand the drugs are creating.

Conexeu is making a two-part bet. First, that GLP-1 adoption has created a large, new patient population no existing injectable was built to serve. The evidence for that half is strong: the patients are largely new to aesthetics², the money is real⁸, and the category leaders are already running studies.¹⁷ Second, that a flowable scaffold designed to support tissue restoration is the right answer. That half rests on preclinical work that met its objectives but isn’t yet peer-reviewed or tested in people.⁶

Here’s what I’d watch over the next 12 months:

1. The 510(k) submission in the first quarter of 2027, which the company reaffirmed as on track on Oct. 6, 2026, subject to FDA review.⁷
2. Peer-reviewed publication of the P.R.O.O.F. data.
3. The terms of the next financing, which will show how much dilution the plan requires.
4. Any aesthetics partnership with a larger player, which would signal outside validation and share the cost of the PMA road.

The proposition here is a watch list, not a trade: put CNXU on it with two triggers, the peer-reviewed P.R.O.O.F. publication and the first-quarter 2027 filing, and read the 10-Q and the July 7 and October 6 releases first, about an hour’s work. Talk to a qualified financial advisor before deciding anything.

Conexeu Sciences · Nasdaq: CNXUDownload CNXU Corporate PresentationDownload the Presentation →